CH50: A revisited hemolytic complement consumption assay for evaluation of nanoparticles and blood plasma protein interaction

Current Drug Delivery

Volumn 8, Issue 3, 2011, Pages 290-298

  Meerasa, Ameena ^a   Huang, Jasper G ^a   Gu, Frank X ^a  

^a UNIVERSITY OF WATERLOO   (Canada)

Author keywords

CH50 assay; Complement activation; Hemolytic assay; Nanoparticles; Opsonization; Protein interaction; Stealth; Toxicity

Indexed keywords

NANOPARTICLE;

ARTICLE; COMPLEMENT ACTIVATION; COMPLEMENT SYSTEM; DRUG DELIVERY SYSTEM; DRUG DESIGN; DRUG PROTEIN BINDING; HEMOLYTIC PLAQUE ASSAY; HUMAN; IMAGING SYSTEM; INNATE IMMUNITY; NANOMEDICINE; NONHUMAN; PRIORITY JOURNAL;

EID: 79953773523     PISSN: 15672018     EISSN: None     Source Type: Journal    
DOI: 10.2174/156720111795256165     Document Type: Article

References (63)

1. Moghimi, S. M.; Hunter, A. C.; Murray, J. C. Long-Circulating and Target-Specific Nanoparticles: Theory to Practice. Pharmacol. Rev., 2001, 53, 283-318.
2. Anton, N.; Saulnier, P.; Gaillard, C.; Porcher, E.; Vrignaud, S.; Benoit, J. Aqueous-Core Lipid Nanocapsules for Encapsulating Fragile Hydrophilic and/or Lipophilic Molecules. Langmuir, 2009, 25, 11413-11419.
3. Chonn, A.; Semple, S. C.; Cullis, P. R. B2-Glycoprotein I is a Major Protein Associated with very Rapidly Cleared Liposomes in Vivo, Suggesting a Significant Role in the Immune Clearance of "Non-Self" Particles. The J. Biol. Chem., 1995, 270, 25845-25849.
4. Aqil, A.; Vasseur, S.; Duguet, E.; Passirani, C.; Benoît, J. P.; Roch, A.; Müller, R.; Jérôme, R.; Jérôme, C. PEO Coated Magnetic Nanoparticles for Biomedical Application. Eur. Polym. J., 2008, 44, 3191-3199.
5. Riehemann, K.; Schneider, S.; Luger, T.; Godin, B.; Ferrari, M.; Fuchs, H. Nanomedicine-Challenge and Perspectives. Angew. Chem. Int. Ed., 2009, 48, 872-897.
6. Halma, C.; Daha, M. R.; Van Es, L. A. In Vivo Clearance by the Mononuclear Phagocyte System in Humans: An Overview of Methods and their Interpretation. Clin. exp. Immunol., 1992, 89, 1-7.
7. Owens, D. E.; Peppas, N. A. Opsonization, Biodistribution, and Pharmacokinetics of Polymeric Nanoparticles. Int. J. Pharm., 2006, 307, 93-102.
8. Inglis, J. E.; Radziwon, K. A.; Maniero, G. D. The Serum Complement System: A Simplified Laboratory Exercise to Measure the Activity of an Important Component of the Immune System. Adv. Physiol. Edu., 2008, 32, 317-321.
9. Frank, M. M.; Fries, L. F. The Role of Complement in Inflammation and Phagocytosis. Immunol. Today, 1991, 12, 322-326.
10. Kinoshita, T. Biology of Complement: The Overture. Immunol. Today, 1991, 12, 291-295.
11. Jiskoot, W.; Schie, R.; Carstens, M.; Schellekens, H. Immunological Risk of Injectable Drug Delivery Systems. Pharm. Res., 2009, 26, 1303-1314.
12. Vonarbourg, A.; Passirani, C.; Saulnier, P.; Benoit, J. Parameters Influencing the Stealthiness of Colloidal Drug Delivery Systems. Biomat., 2006, 27, 4356-4373.
13. Kirschfink, M.; Mollnes, T. E. Modern Complement Analysis. Clin. Diagnostic Lab. Immunol., 2003, 10, 982-989.
14. Arima, Y.; Kawagoe, M.; Toda, M.; Iwata, H. Complement Activation by Polymers Carrying Hydroxyl Groups. ACS Appl. Mater. Interfaces, 2009, 1, 2400-2407.
15. Walport, M. J. Complement: First of Two Parts. New Engl. J. Med., 2001, 344, 1508-1066.
16. Moghimi, S. M.; Szebeni, J. Stealth Liposomes and Long Circulating Nanoparticles: Critical Issues in Pharmacokinetics, Opsonization and Protein-Binding Properties. Prog. Lipid Res., 2003, 42, 463-478.
17. Dobrovolskaia, M. A.; Aggarwal, P.; Hall, J. B.; McNeil, S. E. Preclinical Studies to Understand Nanoparticle Interaction with the Immune System and its Potential Effects on Nanoparticle Biodistribution. Mol. Pharm., 2008, 5, 487-495.
18. Dobrovolskaia, M. A.; Patri, A. K.; Zheng, J.; Clogston, J. D.; Ayub, N.; Aggarwal, P.; Neun, B. W.; Hall, J. B.; McNeil, S. E. Interaction of Colloidal Gold Nanoparticles with Human Blood: Effects on Particle Size and Analysis of Plasma Protein Binding Profiles. Nanomed.: Nanotechnol. Biol. Med., 2009, 5, 106-117.
19. Gessner, A.; Lieske, A.; Paulke, B.; Müller, R. H. Functional Groups on Polystyrene Model Nanoparticles: Influence on Protein Adsorption. J. Biomed. Mater. Res., 2003, 65A, 319-326.
20. Goppert, T. M.; Muller, R. H. Adsorption Kinetics of Plasma Proteins on Solid Lipid Nanoparticles for Drug Targeting. Int. J. Pharm., 2005, 302, 172-186.
21. Goppert, T. M.; Muller, R. H. Protein Adsorption Patterns on Poloxamer-and Poloxamine-Stabilized Solid Lipid Nanoparticles (SLN). Eur. J. Pharm. Biopharm., 2005, 60, 361-372.
22. Labarre, D.; Vauthier, C.; Chauvierre, C.; Petri, B.; Muller, R.; Chehimi, M. M. Interactions of Blood Proteins with Poly(Isobutylcyanoacrylate) Nanoparticles Decorated with a Polysaccharidic Brush. Biomat., 2005, 26, 5075-5084.
23. Leroux, J.; De Jaeghere, F.; Anner, B.; Doelker, E.; Gurny, R. An Investigation on the Role of Plasma and Serum Opsonins on the Internalization of Biodegradable Poly(D, L-Lactic Acid) Nanoparticles by Human Monocytes. Life Sci. Including Pharmacol. Lett., 1995, 57, 695-703.
24. Allémann, E.; Gravel, P.; Leroux, J.; Balant, L.; Gurny, R. Kinetics of Blood Component Adsorption on Poly(D, L_lactic Acid) Nanoparticles: Evidence of Complement C3 Component Involvement. J. Biomed. Mater. Res., 1997, 37, 229-234.
25. Fang, C.; Shi, B.; Pei, Y. Y.; Hong, M. H.; Wu, J.; Chen, H. Z. In Vivo Tumor Targeting of Tumor Necrosis Factor-_-Loaded Stealth Nanoparticles: Effect of MePEG Molecular Weight and Particle Size. Eur. J. Pharm. Sci., 2006, 27, 27-36.
26. Meng, F.; Engbers, G. H. M.; Feijen, J. Polyethylene glycol-grafted Polystyrene Particles. J. Biomed. Mater. Res., 2004, 70A, 49-58.
27. Zahr, A. S.; Davis, C. A.; Pishko, M. V. Macrophage Uptake of Core_Shell Nanoparticles Surface Modified with Poly(Ethylene Glycol). Langmuir, 2006, 22, 8178-8185.
28. Gref, R.; Lück, M.; Quellec, P.; Marchand, M.; Dellacherie, E.; Harnisch, S.; Blunk, T.; Müller, R. H. 'Stealth' Corona-Core Nanoparticles Surface Modified by Polyethylene Glycol (PEG): Influences of the Corona (PEG Chain Length and Surface Density) and of the Core Composition on Phagocytic Uptake and Plasma Protein Adsorption. Colloids and Surfaces B: Biointerfaces, 2000, 18, 301-313.
29. Moore, A.; Weissleder, R.; Bogdanov, A. Uptake of dextran-coated Monocrystalline Iron Oxides in Tumor Cells and Macrophages. J. Magn. Reson. Imaging, 1997, 7, 1140-1145.
30. Kim, H. R.; Andrieux, K.; Delomenie, C.; Chacun, H.; Appel, M.; Desmaële, D.; Taran, F.; Georgin, D.; Couvreur, P.; Taverna, M. Analysis of Plasma Protein Adsorption Onto PEGylated Nanoparticles by Complementary Methods: 2-DE, CE and Protein Lab-on-Chip® System. Electrophor., 2007, 28, 2252-2261.
31. Kim, H. R.; Andrieux, K.; Gil, S.; Taverna, M.; Chacun, H.; Desmaële, D.; Taran, F.; Georgin, D.; Couvreur, P. Translocation of Poly(Ethylene Glycol-Co-Hexadecyl)Cyanoacrylate Nanoparticles into Rat Brain Endothelial Cells: Role of Apolipoproteins in Receptor-Mediated Endocytosis. Biomacromol., 2007, 8, 793-799.
32. Delgado, A. D. S.; Léonard, M.; Dellacherie, E. Surface Properties of Polystyrene Nanoparticles Coated with Dextrans and Dextran-PEO Copolymers. Effect of Polymer Architecture on Protein Adsorption. Langmuir, 2000, 17, 4386-4391.
33. Jaulin, N.; Appel, M.; Passirani, C.; Baratt, G.; Labarre, D. Reduction of the Uptake by a Macrophagic Cell Line of Nanoparticles Bearing Heparin Or Dextran Covalently Bound to Poly(methy1 Methacrylate). J. Drug Targeting, 2000, 8, 165-172.
34. Lück, M.; Schröder, W.; Paulke, B.-.; Blunk, T.; Müller, R. H. Complement Activation by Model Drug Carriers for Intravenous Application: Determination by Two-Dimensional Electrophoresis. Biomat., 1999, 20, 2063-2068.
35. Passirani, C.; Barratt, G.; Devissaguet, J.; Labarre, D. Interactions of Nanoparticles Bearing Heparin Or Dextran Covalently Bound to Poly(Methyl Methacrylate) with the Complement System. Life Sci. Including Pharmacol. Lett., 1998, 62, 775-785.
36. Vonarbourg, A.; Passirani, C.; Saulnier, P.; Simard, P.; Leroux, J. C.; Benoit, J. P. Evaluation of Pegylated Lipid Nanocapsules Versus Complement System Activation and Macrophage Uptake. J. Biomed. Mater. Res., 2006, 78A, 620-628.
37. Lemarchand, C.; Gref, R.; Passirani, C.; Garcion, E.; Petri, B.; Muller, R.; Costantini, D.; Couvreur, P. Influence of Polysaccharide Coating on the Interactions of Nanoparticles with Biological Systems. Biomat., 2006, 27, 108-118.
38. Gbadamosi, J. K.; Hunter, A. C.; Moghimi, S. M. PEGylation of Microspheres Generates a Heterogeneous Population of Particles with Differential Surface Characteristics and Biological Performance. FEBS Lett., 2002, 532, 338-344.
39. Jaskowski, T. D.; Martins, T. B.; Litwin, C. M.; Hill, H. R. Comparison of Three Different Methods for Measuring Classical Pathway Complement Activity. Clin. Diagnostic Lab. Immunol., 1999, 6, 137-139.
40. Ptak, J.; Lochman, J. Immunoadsorption Therapy and Complement Activation. Transfusion Apheresis Sci., 2005, 32, 263-267.
41. Ishida, T.; Atobe, K.; Wang, X.; Kiwada, H. Accelerated Blood Clearance of PEGylated Liposomes upon Repeated Injections: Effect of Doxorubicin-Encapsulation and High-Dose First Injection. J. Control. Release, 2006, 115, 251-258.
42. Marjan, J.; Xie, Z.; Devine, D. V. Liposome-Induced Activation of the Classical Complement Pathway does Not Require Immunoglobulin. BBA-Biomembranes, 1994, 1192, 35-44.
43. Mosqueira, V. C. F.; Legrand, P.; Gulik, A.; Bourdon, O.; Gref, R.; Labarre, D.; Barratt, G. Relationship between Complement Activation, Cellular Uptake and Surface Physicochemical Aspects of Novel PEG-Modified Nanocapsules. Biomat., 2001, 22, 2967-2979.
44. Passirani, C.; Barratt, G.; Devissaguet, J.; Labarre, D. Long-Circulating Nanopartides Bearing Heparin Or Dextran Covalently Bound to Poly(Methyl Methacrylate). Pharm. Res., 1998, 15, 1046-1050.
45. Peracchia, M. T.; Vauthier, C.; Passirani, C.; Couvreur, P.; Labarre, D. Complement Consumption by Poly(Ethylene Glycol) in Different Conformations Chemically Coupled to Poly(Isobutyl 2-Cyanoacrylate) Nanoparticles. Life Sci. Including Pharmacol. Lett., 1997, 61, 749-761.
46. nd ed.; Thomas: Springfield, Illinois, USA, 1961.
47. Vittaz, M.; Bazile, D.; Spenlehauer, G.; Verrecchia, T.; Veillard, M.; Puisieux, F.; Labarre, D. Effect of PEO Surface Density on Long-Circulating PLA-PEO Nanoparticles which are very Low Complement Activators. Biomat., 1996, 17, 1575-1581.
48. Bjerrum, O. J. Crossed Immunoelectrophoresis: An Alternative Method for Identification, Quantification and Characterization of Membrane Proteins. Experientia, 1974, 30, 831-832.
49. Bertholon, I.; Vauthier, C.; Labarre, D. Complement Activation by Core-Shell Poly(Isobutylcyanoacrylate)-Polysaccharide Nanoparticles: Influences of Surface Morphology, Length, and Type of Polysaccharide. Pharm. Res., 2006, 23, 1313-1323.
50. Laine, A.; Ducourouble, M. P.; Hannothiaux, M. H. Identification of Proteins by Crossed Immunoelectrophoresis with a Trap-Gel. Anal. Biochem., 1987, 161, 39-44.
51. Devine, D. V.; Wong, K.; Serrano, K.; Chonn, A.; Cullis, P. R. Liposome-complement Interactions in Rat Serum: Implications for Liposome Survival Studies. BBA-Biomembranes, 1994, 1191, 43-51.
52. Ameller, T.; Marsaud, V.; Legrand, P.; Gref, R.; Barratt, G.; Renoir, J. Polyester_Poly(Ethylene Glycol) Nanoparticles Loaded with the Pure Antiestrogen RU 58668: Physicochemical and Opsonization Properties. Pharm. Res., 2003, 20, 1063-1070.
53. Yague, C.; Moros, M.; Grazu, V.; Arruebo, M.; Santamaria, J. Synthesis and Stealthing Study of Bare and PEGylated Silica Micro-and Nanoparticles as Potential Drug-Delivery Vectors. Chem. Eng. J., 2007, 137, 45-53.
54. Yang, A.; Liu, W.; Li, Z.; Jiang, L.; Xu, H.; Yang, X. Influence of Polyethyleneglycol Modification on Phagocytic Uptake of Polymeric Nanoparticles Mediated by Immunoglobulin G and Complement Activation. J. Nanosci. Nanotechnol., 2010, 10, 622-628.
55. Arima, Y.; Toda, M.; Iwata, H. Complement Activation on Surfaces Modified with Ethylene Glycol Units. Biomat., 2008, 29, 551-560.
56. Socha, M.; Bartecki, P.; Passirani, C.; Sapin, A.; Damgé, C.; Lecompte, T.; Barré, J.; El Ghazouani, F.; Maincent, P. Stealth Nanoparticles Coated with Heparin as Peptide Or Protein Carriers. J. Drug Targeting, 2009, 17, 575-585.
57. Bradley, A. J.; Devine, D. V.; Ansell, S. M.; Janzen, J.; Brooks, D. E. Inhibition of Liposome-Induced Complement Activation by Incorporated Poly(Ethylene Glycol)-Lipids. Arch. Biochem. Biophys., 1998, 357, 185-194.
58. Cenni, E.; Granchi, D.; Avnet, S.; Fotia, C.; Salerno, M.; Micieli, D.; Sarpietro, M. G.; Pignatello, R.; Castelli, F.; Baldini, N. Biocompatibility of Poly(d, l-Lactide-Co-Glycolide) Nanoparticles Conjugated with Alendronate. Biomat., 2008, 29, 1400-1411.
59. Szebeni, J.; Muggia, F. M.; Alving, C. R. Complement Activation by Cremophor EL as Possible Contributor to Hypersensitivity to Paclitaxek: And in Vitro Study. J. Natl. Cancer Institute, 1998, 90, 300-306.
60. Aggarwal, P.; Hall, J. B.; McLeland, C. B.; Dobrovolskaia, M. A.; McNeil, S. E. Nanoparticle Interaction with Plasma Proteins as it Relates to Particle Biodistribution, Biocompatibility and Therapeutic Efficacy. Adv. Drug Deliv. Rev., 2009, 61, 428-437.
61. Béduneau, A.; Saulnier, P.; Anton, N.; Hindré, F.; Passirani, C.; Rajerison, H.; Noiret, N.; Benoit, J. Pegylated Nanocapsules Produced by an Organic Solvent-Free Method: Evaluation of their Stealth Properties. Pharm. Res., 2006, 23, 2190-2199.
62. Fischer, H. C.; Chan, W. C. Nanotoxicity: The Growing Need for in Vivo Study. Curr. Opin. Biotechnol., 2007, 18, 565-571.
63. Layre, A.; Couvreur, P.; Chacun, H.; Richard, J.; Passirani, C.; Requier, D.; Benoit, J. P.; Gref, R. Novel Composite Core-Shell Nanoparticles as Busulfan Carriers. J. Control. Release, 2005, 111, 271-280.